12:00 AM
 | 
Dec 11, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Theralux: Phase I/II

Interim analysis of data from 14 patients who had failed to achieve or maintain a cytogenetic response or could not tolerate interferon therapy showed an overall survival rate of 85...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >